3rd Quarter - Report

EISAI INC. for EISAI INC.

Firm
Client
Income
—
Expenses
$400,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Regulatory and legislative health care issues impacting pricing and access Implementation of P.L. 115-176 Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act of 2017 Implementation of Chronic Care Act of 2017 Regulatory and legislative health care issues, including the 340B program Issues related to diagnosis and treatment of obesity Drug Cost and Pricing Issues related to the diagnosis and treatment of Alzheimer's Disease FDA Guidance on Alzheimer's Disease Drug Development

LobbyistCovered position, as disclosed
TIMOTHY CLARK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Copyright/Patent/Trademark CPT

Ongoing discussions and updates on Amicus petition for certiori in Helsinn Healthcare SA v Teva Pharmaceuticals USA Inc., Teva Pharmaceutical Industries, Ltd.

LobbyistCovered position, as disclosed
TIMOTHY CLARK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Potential pharmaceutical reimbursement cuts (offsets) and potential inclusion of Medicare coverage of FDA-approved obesity drugs. H.R. 1953/S. 830 - Treat and Reduce Obesity Act of 2017 Revisions to Medicare reimbursement programs to cover obesity products Changes to reimbursement structure of Medicare Part D program

LobbyistCovered position, as disclosed
TIMOTHY CLARK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 1953 (115th), S. 830 (115th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.